Publication

Trends in Anterior Lumbar Interbody Fusion in the United States: A MarketScan Study From 2007 to 2014

Journal Paper/Review - Jan 1, 2020

Units
PubMed
Doi

Citation
Varshneya K, Medress Z, Jensen M, Azad T, Rodrigues A, Stienen M, Desai A, Ratliff J, Veeravagu A. Trends in Anterior Lumbar Interbody Fusion in the United States: A MarketScan Study From 2007 to 2014. Clin Spine Surg 2020; 33:E226-E230.
Type
Journal Paper/Review (English)
Journal
Clin Spine Surg 2020; 33
Publication Date
Jan 1, 2020
Issn Electronic
2380-0194
Pages
E226-E230
Brief description/objective

BACKGROUND
Although the incidence of spinal fusions has increased significantly in the United States over the last quarter century, national trends of anterior lumbar interbody fusion (ALIF) utilization are not known.

PURPOSE
The objective of this study was to characterize trends, clinical characteristics, risk factors associated with, and outcomes of ALIF in the United States.

STUDY DESIGN
This was an epidemiological study using national administrative data from the MarketScan database.

METHODS
Using a large administrative database, we identified adults who underwent ALIF in the United States from 2007 to 2014. The incidence of ALIF was studied longitudinally over time and across geographic regions in the United States. Data related to postoperative complications, length of stay, readmission, and cost were collected.

RESULTS
We identified 49,945 patients that underwent ALIF in the United States between 2007 and 2014. The total number of ALIF procedures increased from 3650 in 2007 to 6151 in 2014, accounting for an average increase of 24.07% annually. The Southern United States performed the highest number of ALIFs. The most common conditions treated were degenerative disc disease and spondylolisthesis. Over one third of patients (34.6%) underwent multilevel fusion. The most common complications were iron deficiency anemia, urinary tract infections, and pulmonary complications. Hospital and physician pay increased significantly during the study period.

CONCLUSIONS
For the first time in our knowledge, we identified national trends in ALIF utilization, outcomes, and cost using a large administrative database. Our study reaffirms prior work that has demonstrated low rates of complications, mortality, and readmission following ALIF.

LEVEL OF EVIDENCE
Level III.